Wintermute Biomedical are excited our ZosterEase Phase Ib clinical trial’s patient recruitment is now fulfilled.
Preliminary safety results expected shortly. Read more here.
Preliminary safety results expected shortly. Read more here.
A Topical Therapy to Treat Shingles and
Shingles-induced Pain
Our priority is researching and developing our undecylenic acid-based formulation, Solexan™, for shingles and shingles pain.
Wintermute recruited 30 shingles patients for a Phase Ib Clinical Trial to test Solexan™, a potential new therapy for shingles lesions and shingles pain. Results expected soon.
Who Participated?
30 adults aged 18 and over.
Had visible shingles rash of no more than 10 days before Solexan™ therapy commencement.
ZosterEase's Clinical Milestones
Robust double-blind study investigating Solexan's™ safety and tolerability.
Advisory Board includes world-leading shingles clinical and scientific experts.
Solexan's™ Investigating Benefits
First topical therapy directly targeting shingles infection and associated pain.
An adjunct therapy for patients, particularly those not receiving oral antivirals within 3 days of symptoms onset.
Positive compliance as patients can self apply as topical application.
What's Next ??
We are now actively planning for a Phase II trial to investigate Solexan's ™efficacy for:
* shingles lesion speed of healing
* acute pain reduction
* chronic PHN reduction and prevention
* Commencement planned for Q1 2026
Learn more about the ZosterEase Phase I trial here.
Shingles (Herpes Zoster) is caused by the Varicella Zoster Virus (VZV). Primary infection with the virus causes Chicken Pox, usually in children. After symptoms subside, the virus lies dormant in nerves, sometimes for decades. Shingles occurs when the virus reactivates, typically brought on by stress or a weakened immune system. Shingles is most common in the elderly population, and one in three people will develop shingles in their lifetime.
Shingles is a painful disease, with a painful rash presenting on the torso, and sometimes on the face and limbs. Symptoms typically subside within seven to ten days, but in some patients, shingles can cause other medical complications. One in five people over 50 will develop post-herpetic neuralgia, pain that remains after symptoms have resolved. In some cases, pain can remain for months or years; 15% of patients experience pain for years, causing a significant burden to their quality of life.
The current frontline treatment for shingles is oral antivirals. Unfortunately, these drugs are only effective if given within three days of symptom onset, meaning many patients are left with only painkillers to treat the disease.
Learn more about shingles here.
Solexan™ is an innovative topical treatment being investigated for shingles and shingles-related pain. As a topical foam, Solexan™ can be easily applied to shingles lesions, making it simple for patients to self-administer.
Solexan™ has already been FDA-registered as a topical antifungal, meaning its safety profile is already well established.
In collaboration with Professor Jennifer Moffat at Upstate Medical University NY, we have found encouraging evidence that Solexan™ can penetrate the skin to directly target the shingles virus.
We believe this could be the key to reducing shingles-induced pain and speeding up healing.
